Wegovy’s new pricing could save you $1,200—but it’s not for everyone

Novo Nordisk just launched a new subscription program for Wegovy customers. 

In an announcement Tuesday, the Danish GLP-1 maker said the new program will help “reduce cost uncertainty” so that people can maintain access to their obesity drugs. Wegovy contains semaglutide, a glucagon-like peptide-1 receptor agonist used for chronic weight management. Novo Nordisk also promised savings of up to $600 per year for the pill form of the drug and up to $1,200 per year for the injections with a 12-month subscription. 

Eligible patients can choose the self-pay options that work best for them. A three-month plan will cost users $329 per month. A six-month plan is $299 per month. And a 12-month subscription comes with a monthly fee of just $249.

“The new Wegovy subscription program removes barriers, providing people who enroll with a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment,” said Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk, in the announcement. 

Cinca continued: “By providing predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program aims to support a more manageable way for people to stay on treatment and focus on achieving meaningful, sustainable weight loss outcomes.”

The subscription options are now available through Ro, WeightWatchers, LifeMD, Hims & Hers, and Sesame. The announcement noted that it will be made available through even more services soon.

Novo Nordisk’s announcement comes as the company and Hims & Hers recently entered a partnership, ending a legal battle over copycat versions of Novo’s medications being sold on the telehealth platform for a third of the price. The announcement of the deal seemed to confirm, as does Tuesday’s announcement, that Novo Nordisk hopes to continue its expansion. 

The expansion makes sense, given the company’s sales slowed in 2025, mostly due to increased competition from Eli Lilly, along with other competitors. Earlier this year, Lilly’s stocks surged after it introduced its KwikPen treatment, made for more convenient injections, as the company seemed to be pulling ahead in the weight-loss medication market.

According to a recent Yahoo Finance report, Lilly is still dominating the market. Its Q4 revenue increased 43%, to $19.3 billion, while Novo Nordisk said it expected sales to decline between 5% and 13% this year.

View the full article